2279 (2279) Fair Value & Analysis

Healthcare · Market cap HK$1.0B

2 2279 2279 · HK

PriceHK$2.07

Fair ValueHK$3.74

Upside+80.7%

Quality75/100

Watch 2279 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$2.81 – HK$4.68

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Share price −1.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.12 – HK$3.40 · fair‑value band HK$2.81 – HK$4.68 · the HK$2.07 price screens below the HK$3.74 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2279 (2279) currently trades at HK$2.07, while our model-based Fair Value estimate is HK$3.74 — implying the stock looks roughly 80.7% undervalued today. We read business quality at 75/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2279 generated revenue of HK$1.8B at a net margin of 4.1%. Revenue grew 4.7% year over year. It earns a return on equity of 9.8%. The stock trades on a trailing P/E of 12.2. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.8B

Revenue growth (YoY) +4.7%

Net margin 4.1%

Return on equity 9.8%

Free cash flow HK$477M FY2025

P/E ratio 12.2

More key figures

Operating margin 8.0%

EPS (TTM) HK$0.0600

Dividend yield 3.7%

EPS growth (YoY) -64.8%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2279 reported revenue of HK$1.8B in FY2025 versus HK$2.2B in FY2021, a compound −4.4%/yr. Reported net income was HK$73.7M in FY2025, compounding −11.5%/yr from FY2021.

Revenue −4.4%/yr

FY21 HK$2.2B

FY22 HK$1.4B

FY23 HK$1.8B

FY24 HK$1.8B

FY25 HK$1.8B

Net income −11.5%/yr

FY21 HK$120M

FY22 −HK$85.9M

FY23 −HK$546M

FY24 −HK$226M

FY25 HK$73.7M

Is 2279 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.71 MYR	4.87 MYR	-44%
IHHHF IHHHF	$1.71	$1.17	-32%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2279 (2279) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$3.74 versus a price of HK$2.07 — about +81% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2279?

Our model-based fair value for 2279 is HK$3.74 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.07.

What is the quality score of 2279?

2279 has a Quality Score of 75/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2279 (2279)?

2279 reported trailing-twelve-month revenue of about HK$1.8B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2279?

The net profit margin of 2279 is about 4.1%, meaning it keeps roughly 4.1% of revenue as net income. Based on the latest reported figures.

Does 2279 pay a dividend?

2279 currently shows a dividend yield of about 3.69% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.